Dose-related periorbital edema following sorafenib in a patient with acute myeloid leukemia

Area of Science:

• Hematology
• Pharmacology
• Oncology

Background:

• Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
• FLT3 mutations are common in AML and are targeted by specific therapies.
• Sorafenib and voriconazole are medications used in cancer treatment and antifungal management, respectively.

Observation:

• A case study detailing a patient with FLT3-mutated AML.
• The patient developed periorbital edema, a dose-related adverse event.
• This edema occurred during concurrent treatment with sorafenib and voriconazole.

Findings:

• Sorafenib is a tyrosine kinase inhibitor that can affect various cellular pathways.
• Platelet-derived growth factor receptor (PDGFR) inhibition by sorafenib is a potential mechanism for edema.
• Dose reduction of sorafenib led to the resolution of periorbital edema.

Implications:

• Clinicians should monitor for periorbital edema in patients on sorafenib, especially with voriconazole.
• Sorafenib dose reduction may be a viable strategy to manage this adverse event.
• Understanding drug interactions and mechanisms of adverse events is crucial for optimizing cancer therapy.